We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

EBS Emergent Biosolutions Inc

0.21 (9.81%)
Dec 01 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 2,161,007
Bid Price
Ask Price
News -
Day High 2.46


52 Week Range


Day Low 2.01
Share Name Share Symbol Market Stock Type
Emergent Biosolutions Inc EBS NYSE Common Stock
  Price Change Price Change % Share Price Last Trade
0.21 9.81% 2.35 19:00:00
Open Price Low Price High Price Close Price Previous Close
2.15 2.01 2.46 2.39 2.14
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
10,449 2,161,007 US$ 2.27 US$ 4,913,631 - 1.81 - 16.6643
Last Trade Type Quantity Price Currency
18:59:55 3 US$ 2.36 USD

Emergent Biosolutions Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.67B 51.81M - 1.12B -223.8M -4.32 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Emergent Biosolutions News

Date Time Source News Article
11/28/202306:15Edgar (US Regulatory)Form 8-K - Current report
11/28/202305:59GlobeNewswire Inc.Emergent BioSolutions Receives $75 Million Contract Option..
11/24/202306:30GlobeNewswire Inc.Emergent BioSolutions Receives NYSE Notice Regarding Delayed..
11/24/202306:17Edgar (US Regulatory)Form 8-K - Current report
11/16/202315:11Edgar (US Regulatory)Form 8-K - Current report
11/14/202318:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/14/202318:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/14/202318:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
11/09/202315:22Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form..
11/08/202316:38GlobeNewswire Inc.Emergent BioSolutions Reports Third Quarter 2023 Financial..
11/08/202315:21Edgar (US Regulatory)Form 8-K - Current report
10/30/202315:45GlobeNewswire Inc.UPDATE: Emergent BioSolutions to Release Third Quarter 2023..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No EBS Message Board. Create One! See More Posts on EBS Message Board See More Message Board Posts

Historical EBS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.002.461.962.101,439,4520.3517.5%
1 Month2.152.461.812.141,450,2730.209.3%
3 Months4.394.681.812.941,739,154-2.04-46.47%
6 Months8.579.961.814.891,915,775-6.22-72.58%
1 Year12.4016.66431.817.481,677,872-10.05-81.05%
3 Years82.74127.201.8126.851,029,154-80.39-97.16%
5 Years73.75137.611.8138.23826,197-71.40-96.81%

Emergent Biosolutions Description

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |